Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 24, 2019 at 06:57 am EDT
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 214.993 million compared to CNY 325.467 million a year ago. Operating income was CNY 21.588 million compared to CNY 55.799 million a year ago. Net income was CNY 18.896 million compared to CNY 47.340 million a year ago. Basic earnings per share from continuing operations was CNY 0.1181 compared to CNY 0.2959 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
